Physician profile
Arturo E Meade
NPI 1639166556
$67,109.89
in general payments reported to CMS, 2019-2025
46 companies · $9,809 in 2025
The $9,809 reported for 2025 was more than what 93% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,252 · 2020: $5,479 · 2021: $26K · 2022: $13K · 2023: $10K · 2024: $838 · 2025: $9,809.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,475 · Education: $7,089 · Food and Beverage: $3,089 · Travel and Lodging: $1,070.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,475.00 |
| Education | $7,088.99 |
| Food and Beverage | $3,088.91 |
| Travel and Lodging | $1,069.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $51,757.38 | 2019-2025 | Nucala, Trelegy Ellipta, Shingrix |
| Intuitive Surgical, INC. | $7,955.33 | 2024-2025 | |
| Astrazeneca Pharmaceuticals Lp | $2,270.73 | 2019-2025 | Fasenra, Tezspire |
| Pulmonx Corporation | $818.46 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $724.78 | 2019-2025 | Ofev |
| Regeneron Healthcare Solutions, INC. | $464.25 | 2020-2025 | Dupixent |
| Actelion Pharmaceuticals US, INC. | $292.95 | 2019-2023 | Opsumit, Uptravi |
| Genzyme Corporation | $225.59 | 2021-2025 | |
| United Therapeutics Corporation | $224.46 | 2019-2025 | Tyvaso, Tyvaso |
| Jazz Pharmaceuticals INC. | $186.67 | 2021-2023 | |
| Sunovion Pharmaceuticals INC. | $169.50 | 2019 | |
| Mylan Specialty L.P. | $165.88 | 2019-2024 | Yupelri |
| Genentech USA, INC. | $165.75 | 2019 | |
| Grifols USA, LLC | $146.94 | 2019-2025 | Prolastin-C Liquid |
| Siemens Medical Solutions USA, INC. | $138.49 | 2024 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arturo Meade listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.